Radar

XtalPi

以人工智能和机器人技术为驱动力，晶泰致力于用量子物理、AI、云计算、机器人实验等前沿技术领域打造了面向未来产业的创新型研发平台。该平台凭借共性技术集成优势，满足微观分子世界探索的需求。广泛赋能生物医药行业、新材料、石油化工、新能源等领域，为未来产业发展注入澎湃新动力。

Company profile updated 10/3/2026

ChinaLife Sciences Drug Discovery
Company website ↗

Company overview

Official name
XtalPi
Headquarters / region
China
Categories
Life Sciences Drug Discovery
Status
Active

Funding overview

Funding events
10
Latest disclosed event
1/27/2026

Scroll sideways for all funding fields.

DateStageAmountInvestorsData note
Post Ipo DebtUSD 364,760,522—Licensed historical data
Post Ipo EquityUSD 268,613,860—Licensed historical data
Post Ipo EquityUSD 144,457,642—Licensed historical data
Post Ipo DebtUSD 692,070,259China Construction BankLicensed historical data
Series DUSD 400,000,0005Y Capital、HOPU Investment Management Company、HSG、OrbiMed、Sino Biopharmaceutical、Taihill Venture、ZWC PartnersLicensed historical data
Series CUSD 318,800,0005Y Capital、China Life Healthcare Fund、CITIC Capital Holdings、CMB International's Telecom Fund.、HSG、IMO Ventures、Mirae Asset、Morningside、Oceanpine Capital、PICC Capital Investment Management、Shunwei Capital、SIG China (SIG Asia Investments)、SoftBank Vision Fund、TencentLicensed historical data
Series BUSD 46,000,000China Life Healthcare Fund、HT Capital、SIG China (SIG Asia Investments)、Yael Capital Management LimitedLicensed historical data
Series BUSD 15,000,000Alphabet、HSG、TencentLicensed historical data
Series AUSD 60,751ZhenFundLicensed historical data
Series AUSD 1,231,952Frees Fund、ZhenFundLicensed historical data